<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964455</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO201610003</org_study_id>
    <nct_id>NCT02964455</nct_id>
  </id_info>
  <brief_title>Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective, Open-label, Phase I Study of Docetaxel and Nedaplatin Twice Weekly in Combination With Chest Radiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase I study is to determine the maximum tolerated dose and dose limiting toxicity of
      docetaxel and nedaplatin prescribed twice weekly in combination with concurrent chest
      radiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>From start of week 1 to 2 weeks after end of combination treatment (combination treatment = 6.5 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>From start of week 1 to 2 weeks after end of combination treatment (combination treatment = 6.5 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and severity of adverse events</measure>
    <time_frame>From start of week 1 to 6 weeks after end of combination treatment (combination treatment = 6.5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>8 weeks after end of combination treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic plasma concentration of docetaxel and nedaplatin</measure>
    <time_frame>From start of week 1 to the end of combination treatment (6.5 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Nedaplatin + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks during chest radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks during chest radiation</description>
    <arm_group_label>Docetaxel + Nedaplatin + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks of during chest radiation</description>
    <arm_group_label>Docetaxel + Nedaplatin + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chest radiation</intervention_name>
    <description>continuous chest radiation at 64 Gy/32f</description>
    <arm_group_label>Docetaxel + Nedaplatin + Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed esophageal squamous cell carcinoma

          -  Inoperable stage II-IVa (UICC 2002; sixth edition), confirmed by contrast- enhanced
             computed tomography,endoscopic ultrasonography, barium esophagram, emission computed
             tomography and/or positron emission tomography/computed tomography.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 1-2

          -  Estimated life expectancy of at least 12 weeks

          -  Charlson comorbidity index≤4

          -  Adequate bone marrow function: white blood cells grade 0 or 1,absolute neutrophils
             grade 0 or 1, platelets grade 0, haemoglobin grade 0 or 1

          -  Adequate renal function: creatinine grade 0 or 1

          -  Adequate liver function: serum bilirubin grade 0 or 1, alanine aminotransferase and
             aspartate aminotransferase &lt;2 times of the upper normal limit

          -  Weight loss≤15% during 6 months prior to diagnosis

          -  Forced expiratory volume second≥1L

        Exclusion Criteria:

          -  Prior history of malignancy, except for nonmelanoma skin carcinoma or cervical
             carcinoma in situ

          -  Previous anti-tumor therapy, including surgery, chemotherapy or radiotherapy

          -  Contraindication for chemotherapy or radiotherapy

          -  Malignant pleural or pericardial effusion

          -  Women in pregnancy or lactation period

          -  Women who has the probability of pregnancy without contraception

          -  Weight loss≥15% during 3 months prior to diagnosis

          -  In other clinical trials within 30 days

          -  Addicted in drugs or alcohol, AIDS patients

          -  Uncontrollable seizure or psychotic patients without self-control ability

          -  Severe allergy or idiosyncrasy

          -  Not suitable for this study judged by researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi-Wen Li</last_name>
    <phone>+86-020-87343031</phone>
    <email>liqw@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Liu, Prof.</last_name>
    <phone>+86-020-87343031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hui Liu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu, Prof.</last_name>
      <phone>+86-020-87343031</phone>
      <email>liuhui@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Nedaplatin</keyword>
  <keyword>Twice weekly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

